Dr. Madduri on Eligibility for CAR T-Cell Therapy in Myeloma

Video

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses eligibly criteria for patients with multiple myeloma to receive chimeric antigen receptor (CAR) T-cell therapy.

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses eligibly criteria for patients with multiple myeloma to receive chimeric antigen receptor (CAR) T-cell therapy.

There have been very promising data published recently on the use of CAR T-cell therapy for patients with myeloma, says Madduri. The anti-BCMA CAR T-cell therapy bb2121 was granted a breakthrough therapy designation for previously treated patients with relapsed/refractory myeloma in November 2017.

Madduri says that the biggest challenge with CAR T-cell therapy for these patients is slot limitation. There are many patients who want to receive CAR T-cell therapy, but it is a matter of how many slots are available, as well as eligibility. To be eligible for CAR T-cell therapy, a patient with myeloma must have received a proteasome inhibitor, an immunomodulatory drug, and a CD38 antibody. Additionally, the patient must have good hematological counts, and be relapsed and refractory. The patient cannot have had prior BCMA therapy. Madduri says that it is a matter of qualifying at the right time and the number of slots available.

Recent Videos
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Related Content
© 2025 MJH Life Sciences

All rights reserved.